Gastroenterology RACP MCQs Flashcards
RACP 2022 Q13
13.A 56 year old woman has autoimmune hepatitis, hypertension and hyperlipidemia on azathioprine, perindopril and atorvastatin. She develops acute joint pain in her left MTP. Joint aspirate showed calcium pyrophosphate (?) crystals. What is your initial management?
a. Allopurinol
b. Probenicid
c. Feboxustat
d. Benzbromarone
Given that the primary goal is to manage the acute inflammatory symptoms, the correct answer is not explicitly listed in the provided options. The initial management for pseudogout typically includes:
Non-steroidal anti-inflammatory drugs (NSAIDs): Such as indomethacin or naproxen.
Colchicine: Effective for treating acute attacks of pseudogout.
Corticosteroids: If NSAIDs are contraindicated or not tolerated.
Since none of these options (NSAIDs, colchicine, or corticosteroids) are listed, and given that all the provided choices are primarily for urate management, there is no appropriate option for the acute management of pseudogout in this list.
RACP 2022 Q45.
A patient has a new diagnosis of diffuse large B cell lymphoma. He is about to start chemo with RCHOP. As part of his initial work up, his hepatitis B serology shows Hep B surface antigen negative, Hep B core antibody
positive, Hep B surface antibody positive. How would you manage this?
a. Do nothing as patient is immune
b. Check Hep B E antibody
c. Start antivirals
A
Patient is fully cured from past infection and no further intervention is required
(refer to Hepatitis powerpoint - JK)
RACP 2022 Q79
79.”A 64yo M is found to have large cell lymphoma, he is planned to commence
on cyclophosphamide, doxorubicin, vincristine(?), prednisone, and rituximab.
He was screened pre-treatment for hepatitis B, his results are as follows:
HbsAg negative
HbsAb positive
HbcAb positive
Viral load not detected
What is the most appropriate step before commencing chemotherapy?
a. antiviral medications
b. check hepatitis B e antibody
c. hepatitis B vaccine
d. no further treatment
D
Patient is fully cured from previous Hep B infection
(refer to Hepatitis powerpoint - JK)
RACP 2022 Q 85.EMQ:
A patient has been started on isoniazid for pulmonary tuberculosis. What nutritional supplementation does this patient need?
a. B1 (thiamine)
b. B2
c. B3 (niacin)
d. B4
e. B6 (pyridoxine)
f. B12
g. C
h. D
E
RACP 2022 86.EMQ:
A patient has been eating shaved ice for a month after having bariatric surgery. He now presents with ophthalmoplegia, ataxia and nystagmus. What nutritional supplementation does this patient need?
a. B1 (thiamine)
b. B2
c. B3 (niacin)
d. B4
e. B6 (pyridoxine)
f. B12
g. C
h. D
RACP 2022b 6
- What is the pathophysiology of malabsorption in coeliac disease?
A. reduced intestinal surface area
B. reduced brush border dissacharidases
C. increased enteric amylase
D. increased unabsorbed carbohydrates
A
Reduced Intestinal Surface Area (A):
In coeliac disease, the ingestion of gluten leads to an inflammatory response that damages the villi in the small intestine. Over time, this results in villous atrophy, which decreases the surface area available for absorption.
This option is correct because a reduced intestinal surface area directly impacts nutrient absorption, leading to malabsorption.
RACP 2022 Q40.
A patient has macrocytic anaemia and you suspect pernicious anaemia. What is the
most Specific Antibody test?
A. Intrinsic factor
B. Methymalone acid
C. Parietal cell
D. Vitamin B 12
Answer: A. Intrinsic factor
Explanation:
In the context of suspected pernicious anemia, which is a type of macrocytic anemia caused by Vitamin B12 deficiency due to impaired absorption, the most specific antibody test is the Intrinsic Factor antibody test.
Pernicious anemia is characterized by the autoimmune destruction of gastric parietal cells, leading to a lack of intrinsic factor, a protein necessary for the absorption of vitamin B12 in the intestines. Consequently, the presence of antibodies against intrinsic factor is a key indicator of this condition.
Here’s a breakdown of the options:
-
Intrinsic Factor Antibody (A):
- This test specifically detects antibodies against intrinsic factor, which is crucial in diagnosing pernicious anemia. A positive result indicates the presence of autoimmune activity that inhibits vitamin B12 absorption. This test is considered the most specific for pernicious anemia.
- Guidelines such as those from the American Society of Hematology recommend testing for intrinsic factor antibodies when pernicious anemia is suspected.
-
Methylmalonic Acid (B):
- Elevated levels of methylmalonic acid are seen in Vitamin B12 deficiency but are not specific to pernicious anemia alone. While it can help assess Vitamin B12 deficiency, it does not confirm pernicious anemia specifically.
-
Parietal Cell Antibody (C):
- This test detects antibodies against gastric parietal cells. While positive in some cases of pernicious anemia, it is less specific compared to intrinsic factor antibodies.
-
Vitamin B12 (D):
- While low levels of vitamin B12 can indicate deficiency, this test does not specify the underlying cause of the deficiency, such as whether it is due to pernicious anemia or dietary insufficiency.
RCAP 2022 Q48
- What is the mechanism of action of lactulose when used as a laxative?
A. Not broken down by intestinal enzymes and remains in lumen, causing water to
remain in lumen
B. Stimulates intestinal cells to contract, increases intestinal motility
C. Cause increased secretion of fluid into the intestinal lumen and add bulk to stool
D. Reduces surface tension to allow more water to enter stool
Answer: A. Not broken down by intestinal enzymes and remains in lumen, causing water to remain in lumen
Explanation:
Lactulose is a synthetic disaccharide that is not absorbed in the gastrointestinal tract. Its mechanism of action as a laxative involves the following:
- Non-absorption: Lactulose is not broken down by intestinal enzymes, which means it passes through the intestines unchanged.
- Osmotic Effect: As lactulose remains in the lumen, it draws water into the intestines by osmosis. This influx of water increases the volume of the intestinal contents.
- Increased Stool Bulk and Softness: The increase in water content causes the stool to soften and swell, promoting peristalsis and facilitating bowel movements.
- Prebiotic Effects: Additionally, lactulose is fermented by colonic bacteria into short-chain fatty acids, which may also contribute to its laxative effect, although the primary mechanism is its osmotic action.
Conclusion:
Thus, the correct mechanism of action of lactulose as a laxative is that it is not broken down by intestinal enzymes and remains in the lumen, causing water to remain in the lumen. This osmotic effect is what promotes laxation and relief from constipation.
RACP 2022 Q50
- What electrolyte abnormalities occur in refeeding syndrome?
A) K decrease, PO4 decrease, Mg decrease
B) K increase, PO4 decrease, Mg decrease
C) K increase, PO4 increase, Mg increase
D) K decrease, PO4 increase, Mg increase
A
Low PHOSPHATE, low POTASSIUM, low MAGNESIUM
- Caused in prolonged starvation = reduced insulin production causes shrinking of cell as water flows out of cell along with Potassium, Phosphate, Mg
- When starts eating again, there is excessive insulin release = rush of electrolytes and water back into cells = decreased serum concentrations
○ Increased insulin levels also causes ADH release = fluid retention = dilution hypoalbuminemia
○ Increased insulin levels causes reduced thiamine
Need to restart feeding slowly (high fat, low carb diet), monitor and replace
RACP 2022 66. EMQ:
What receptor does this antiemetic act on? Ondansetron
A. 5-HT3
B. Dopamine
C. NK-1
D. Histamine
E. Acetylcholine
Answer: A. 5-HT3
Explanation:
Ondansetron is an antiemetic medication that specifically acts as a selective antagonist of the 5-HT3 receptor, which is a subtype of serotonin receptor. Here’s how it works:
-
5-HT3 Receptor Mechanism:
- The 5-HT3 receptors are located in the central nervous system (CNS) and the gastrointestinal tract.
- When serotonin (5-HT) binds to these receptors, it can trigger nausea and vomiting.
- Ondansetron blocks these receptors, thereby preventing the action of serotonin and effectively reducing the sensation of nausea and the occurrence of vomiting.
-
Clinical Use:
- Ondansetron is commonly used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery.
Conclusion:
Thus, the correct answer is that Ondansetron acts on the 5-HT3 receptor to exert its antiemetic effects.
RACP 2022 67. EMQ: What receptor does this antiemetic act on? Aprepitant
A. 5-HT3
B. Dopamine
C. NK-1
D. Histamine
E. Acetylcholine
Answer: C. NK-1
Explanation:
Aprepitant is an antiemetic that primarily acts as an antagonist of the NK-1 receptor (Neurokinin-1 receptor). Here’s how it works:
-
NK-1 Receptor Mechanism:
- The NK-1 receptor is primarily activated by substance P, a neuropeptide involved in the vomiting reflex.
- Aprepitant inhibits the binding of substance P to the NK-1 receptor in the central nervous system, which helps to prevent nausea and vomiting.
-
Clinical Use:
- Aprepitant is commonly used in combination with other antiemetics (such as 5-HT3 antagonists) to prevent acute and delayed nausea and vomiting associated with chemotherapy.
Conclusion:
Thus, the correct answer is that Aprepitant acts on the NK-1 receptor to provide its antiemetic effects.
RACP 2021a Q36.
A 60 year old man presents with a two week history of pruritis, jaundice, dark urine, pale stools, and 6kg weight loss, but nil abdominal pain. In the month prior, he had a course of augmentin duo forte for a chest infection. He has a background history of a caecal cancer treated with right sided hemicolectomy. He smokes 20 cigarettes per day and drinks 2 standard drinks per day. His observations are: HR 88, BP 125/88, RR 12, temp 36.8C.
An abdominal ultrasound shows a dilated gallbladder with nil stones, dilated CBD to the level of the duodenum, and increased echogenicity throughout the liver. His LFTs are as follows:
Bilirubin 210
Albumin 34
ALT 40
ALP 610
GGT 340
What is the most likely diagnosis?
A. Drug induced liver injury related to Augmentin
B. Alcoholic liver disease
C. Widespread colorectal cancer
D. Head of pancreas cancer
Answer: D. Head of pancreas cancer
Reasoning:
-
Clinical Presentation:
- The patient presents with pruritus, jaundice, dark urine, pale stools, and significant weight loss over two weeks. These symptoms are consistent with cholestasis (the impairment of bile flow).
- The absence of abdominal pain can be notable in cases of pancreatic cancer, especially when the tumor obstructs the bile duct without causing immediate pain.
-
Laboratory Findings:
- The liver function tests (LFTs) show:
- Elevated bilirubin (210 µmol/L), which is indicative of cholestasis.
- Elevated alkaline phosphatase (ALP) (610 U/L) and gamma-glutamyl transferase (GGT) (340 U/L) suggest cholestatic liver disease, often due to obstruction of the bile duct.
- The ALT is mildly elevated, which is less typical for pure obstructive pathology but can be seen in cases of biliary obstruction.
- Albumin levels are normal, which is indicative of the liver’s synthetic function still being intact at this stage.
- The liver function tests (LFTs) show:
-
Imaging Findings:
- The abdominal ultrasound shows:
- A dilated gallbladder and dilated common bile duct (CBD), indicating that bile is not able to flow properly, likely due to an obstruction.
- The absence of gallstones suggests that the obstruction is not due to stones but potentially due to a mass.
- Increased echogenicity throughout the liver can indicate liver disease, and may suggest metastasis or infiltrative processes.
- The abdominal ultrasound shows:
-
History of Colorectal Cancer:
- The patient has a history of caecal cancer treated with a right-sided hemicolectomy. Given his history, the possibility of recurrence or metastasis is significant.
- Cancers of the colon can metastasize to the liver or other structures, and a mass in the head of the pancreas could obstruct the CBD leading to the symptoms presented.
-
Exclusion of Other Options:
- A. Drug-induced liver injury related to Augmentin: While possible, it typically would present with more diffuse liver dysfunction, elevated transaminases, and would not usually cause significant obstruction of bile flow leading to jaundice and pale stools.
- B. Alcoholic liver disease: Given the patient’s low alcohol intake (2 standard drinks per day) and acute presentation with obstruction, this is less likely.
- C. Widespread colorectal cancer: While this is a consideration, the specific symptomatology (especially the biliary obstruction signs and jaundice) aligns more closely with a mass effect typically seen in head of pancreas cancer.
Conclusion:
The combination of the patient’s clinical presentation, lab findings, imaging results, and history supports the diagnosis of head of pancreas cancer, likely causing obstruction of the common bile duct leading to jaundice, pruritus, and pale stools.
RACP 2021b Q46.
A nurse has been exposed to a needlestick injury when caring for a patient. The patient has bloods with
serology is as follows: Hepatitis B surface antigen positive, HIV serology negative and Hepatitis C serology negative. The nurse’s blood tests from an earlier in the year show: Hepatitis B core negative, HIV negative, Hepatitis C negative and Hepatitis B surface antibody > 1000 IU.
What treatment do you suggest?
A. Prophylactic Entacavir
B. Hepatitis B immunoglobulin
C. Reassure and do no investigations
D. Hepatitis surface antigen serology at 6 and 12 weeks
C
RACP 2021a Q71
Q75. What is the histology at GOJ biopsy in Barrett’s oesophagus?
A. Goblet cell hyperplasia
B. Inflammation
C. Intestinal metaplasia
D. (Rhubarb)
C - intestinal metaplasia +/- acid-mucin–containing goblet cells
RACP 2021a Q88
Q88. You review a 24-year-old male who has Crohn’s disease with stricturing ileal disease. He underwent a
resection of bowel including the terminal ileum with primary anastomosis 2 years ago. His current medications
include azithromycin and infliximab.
He now comes to you with persistent diarrhea. You performed further investigations to assess the cause. His
faecal calprotectin was within normal limits. Colonoscopy including biopsy showed a patent ileocolonic anastomosis with no evidence of active inflammation. MRI of the abdomen showed normal bowel calibre without any active inflammation.
What is the most likely cause of his persistent diarrhea?
A. Bile salt malabsorption
B. Clostridium difficile infection
C. Coeliac disease
D. Short gut syndrome
RACP 2021b Q105
Q105. Persistence of which viral component prevents hepatitis B cure?
A. Covalently closed circular DNA
B. Hepatitis B surface antigen
C. Precore protein
D. Pregenomic RNA
A
(refer to Hepatitis powerpoint - JK)
RACP 2021b Q108
Q108. In which part of the gastrointestinal tract are bile salts absorbed?
A. Duodenum
B. Stomach
C. Ileum
D. Jejunum
C - distal ileum
RACP 2021 Q145. What is the most specific autoantibody for diagnosis of autoimmune hepatitis?
A. Anti smooth muscle (anti SMA)
B. Anti liver cytosol 1 (anti LC1)
C. Anti liver kidney microsomal (anti LKM)
D. Anti soluble liver antigen/liver pancreas (anti SLA/LP)
A
RACP 2021 Q148. Acute opioid withdrawal has been reported in patients with end stage liver disease when administered oxycodone-naloxone combination. This is best explained by:
A. Augmentation of endogenous partial agonists
B. Increased absorption due to gastric hyperaemia and gut oedema
C. Increased volume of distribution
D. Shunting of portal circulation to systemic circulation
RACP 2021 Q169 – Which protein releases iron into blood stream from enterocytes?
A. Ferritin
B. Hepcidin
C. Ferroportin
D. Transferrin
E. onwards - rhubarb
Answer: C. Ferroportin
Explanation:
Ferroportin is the key protein responsible for the release of iron from enterocytes (intestinal cells) into the bloodstream. Here’s a breakdown of each option:
-
A. Ferritin:
- Ferritin is a protein that stores iron within cells. It sequesters iron to prevent its free circulation and potential toxicity, but it does not release iron into the bloodstream.
-
B. Hepcidin:
- Hepcidin is a hormone produced by the liver that regulates iron homeostasis. It decreases iron absorption by promoting the internalization and degradation of ferroportin, thus preventing iron release from enterocytes and macrophages. While it plays a crucial role in iron regulation, it does not release iron.
-
C. Ferroportin:
- Ferroportin is the only protein that allows iron to be exported from enterocytes into the blood. When iron is absorbed from the diet, it is stored as ferritin within enterocytes, and ferroportin mediates its transport into the circulation when needed. This action is essential for maintaining systemic iron levels.
-
D. Transferrin:
- Transferrin is a transport protein that binds iron in the bloodstream and delivers it to various tissues, but it does not facilitate the release of iron from enterocytes.
Conclusion:
The protein that releases iron into the bloodstream from enterocytes is C. Ferroportin. This understanding aligns with current knowledge of iron metabolism and regulation in the body.
RACP 2021 Q6. A 70 year old male with a history of Parkinson’s disease presents with nausea and vomiting. Which of the
following medications would most likely cause an exacerbation of the patient’s Parkinson’s disease?
A. Cyclizine
B. Metoclopramide
C. Domperidone
D. Ondanestron
Answer: B. Metoclopramide
Explanation:
In patients with Parkinson’s disease, certain medications can exacerbate symptoms due to their effects on dopamine receptors. Here’s a breakdown of the options provided:
-
A. Cyclizine:
- Cyclizine is an antihistamine used to treat nausea and motion sickness. It has anticholinergic properties and does not typically exacerbate Parkinson’s disease symptoms.
-
B. Metoclopramide:
- Metoclopramide is a dopamine receptor antagonist primarily used to treat nausea and gastroparesis. It blocks D2 dopamine receptors in the central nervous system, which can worsen Parkinson’s disease symptoms by reducing dopaminergic activity. Therefore, this medication is known to exacerbate motor symptoms in patients with Parkinson’s disease.
-
C. Domperidone:
- Domperidone is also a dopamine antagonist, but it primarily works peripherally (in the gastrointestinal tract) and does not cross the blood-brain barrier to the same extent as metoclopramide. It is generally considered safer for patients with Parkinson’s disease compared to metoclopramide.
-
D. Ondansetron:
- Ondansetron is a 5-HT3 receptor antagonist used for nausea and vomiting, especially in chemotherapy. It does not have significant effects on dopaminergic pathways and is not known to exacerbate Parkinson’s symptoms.
Conclusion:
Given the potential for metoclopramide to worsen Parkinson’s disease symptoms due to its central D2 receptor antagonism, the most likely medication to cause an exacerbation of the patient’s Parkinson’s disease is B. Metoclopramide.
RACP 2021 Q25. A 70 year old man has a history of chronic constipation. He presents with abdominal swelling and distension,
abdo pain and vomiting. His abdominal x-ray is shown below. Exact image included in paper.
What is the most likely diagnosis?
A. Obstructive tumour
B. Pseudo obstruction
C. Faecal loading
D. Sigmoid volvulus
RACP 2021
Q55. What is the most likely explanation for persisting malabsorptive symptoms and villous atrophy in patients
with proven coeliac disease?
A. Ongoing dietary gluten intake
B. Pancreatic malabsorption
C. Intestinal Crohn’s disease
D. Collagenous atrophy
RACP 2021
Q97. Which of the listed immunosuppressive medications cause chronic diarrhoea?
A. Anti-thymocyte globulin
B. Tacrolimus
C. Cyclosporin
D. Sirolimus
E. Mycophenolate mofetil
F. Basiliximab
G. (Rhubarb)
H. (Rhubarb)
The correct answer is E. Mycophenolate mofetil.
Key Points for RACP Exam:
• Mycophenolate mofetil (MMF) is commonly associated with gastrointestinal side effects, including chronic diarrhoea, nausea, vomiting, and abdominal pain.
• Mechanism: MMF inhibits inosine monophosphate dehydrogenase, impairing lymphocyte proliferation, but also affects rapidly dividing cells in the gastrointestinal tract, leading to diarrhoea.
• Management: Dose reduction or switching to enteric-coated mycophenolic acid (EC-MPA) can help reduce GI symptoms.
Other Options:
• A. Anti-thymocyte globulin – Causes fever, chills, and serum sickness-like reactions but not chronic diarrhoea.
• B. Tacrolimus – Causes nephrotoxicity, neurotoxicity (tremor, seizures), and hyperglycaemia, but diarrhoea is not a primary side effect.
• C. Cyclosporin – Causes nephrotoxicity, gingival hyperplasia, and hypertension; diarrhoea is uncommon.
• D. Sirolimus – Can cause mouth ulcers and hyperlipidaemia, but diarrhoea is not a prominent side effect.
• F. Basiliximab – Generally well-tolerated; diarrhoea is not a common side effect.
Exam Tip:
For immunosuppressants, focus on their main toxicities (renal, neuro, metabolic, GI). Mycophenolate mofetil is high-yield for GI effects, especially diarrhoea.